| TA70 |
Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241) |
|
-
-
The clinical and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia
This guidance has been partially updated by TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
-
Other information
How this guidance was produced
Background information
This page was last updated: 13 January 2012
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
